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Patients who continue to have symptoms with frequent attacks of asthma despite being adherent to treatment with multiple 
asthma medications, have severe asthma. Severe asthma has significant implications for the affected individual and utilise a 
disproportionate share of the health care costs associated with asthma.        
INTRODUCTION
Asthma is a common disease, with a ris-
ing prevalence throughout the world. In 
South Africa, the prevalence of asthma 
has been estimated to be between 10 
- 15%, although some studies suggest 
an even higher prevalence.1 Most asth-
matics have mild to moderate disease, 
with severe asthma thought to affect 
less than 10% of asthmatics.2  Severe 
asthma has significant implications for 
the affected individual and patients with 
severe asthma also utilise a dispropor-
tionate share of the health care costs 
associated with asthma.
SEVERE ASTHMA
WHAT CONSTITUTES SEVERE 
ASTHMA?
Current guidelines classify asthma 
as severe on the basis of night-time 
symptoms, frequent use of short-acting 
bronchodilators, day-time symptoms 
and reduced lung functions. There are 
many problems with this approach, one 
of which is the poor correlation between 
symptoms and lung functions. In addi-
tion, it is well known that patients and 
doctors both underestimate asthma 
severity. The patient with truly severe 
asthma is someone who continues to 
have symptoms with frequent attacks 
of asthma despite being adherent to 
treatment with multiple asthma medica-
tions.2
Severe asthma in children tends to 
be different from that in adults. Boys 
tend to have more severe asthma than 
girls, but in adulthood a switch occurs 
to a female predominance. Asthmatic 
children with low lung functions and 
early onset of asthma are more likely to 
develop severe asthma, either during 
childhood or as adults. However, some 
adults with severe asthma do not have 
these risk factors, suggesting that other 
mechanisms play a role in the develop-
ment of severe asthma.2
An approach to the patient who has 
severe asthma that is proving difficult to 
control is as follows:
1. Check adherence to therapy.
2.  Check drug delivery system and 
technique.
3.  Assess the environment and trig-
gers.
4.  Consider alternative diagnoses, such 
as post-viral wheezing or gastro-
oesophageal reflux. Check medi-
cal records, re-evaluate the history 
and physical examination, assess 
response to medication, review the 
chest X-ray, lung functions (pre- and 
post-bronchodilator), and allergy 
tests.  Remember that it is especially 
important to consider alternative 
diagnoses in young children.  In 
adult-onset asthma, consider peri-
menstrual asthma, aspirin-sensitive 
asthma and occupational asthma.3 
5.  Consider and treat co-morbid condi-
tions such as allergic rhinitis, sinus-
itis, gastro-oesophageal reflux.
6. Consider psychosocial factors.
OPTIONS FOR THERAPY IN SEVERE 
ASTHMA
Patients with severe asthma should be 
referred to a specialist for assessment 
and control. Optimal therapy depends 
on the resources available. All patients 
with persistent asthma should receive 
preventer medication in the form of in-
haled corticosteroids (ICS). Patients with 
severe asthma require high dose ICS to 
which additional therapy should be add-
ed if available and affordable. There is 
wide variation in the recommended dos-
es of ICS in severe asthma. The South 
African guidelines recommend ICS > 
400 µg/day of beclomethasone (BDP) or 
equivalent for severe asthma in children 
and > 1000 µg/day BDP equivalent for 
severe asthma in adults.4, 5
If control is not achieved with high 
dose ICS, then add-on therapy is pref-
erable to further increasing the dose 
of ICS. Options for add-on therapy are 
an inhaled long-acting ß2 agonist (e.g. 
salmeterol or formoterol) or a leukotriene 
receptor antagonist (e.g. montelukast) 
or low dose sustained-release theophyl-
line. If control is not achieved with high 
dose ICS and one add-on treatment, 
then a second add-on medication may 
be necessary. Oral corticosteroids (CS) 
may be required on a long-term basis 
– this is effective and inexpensive treat-
ment but carries the risk of significant 
side effects, especially in children. The 
potential risks of systemic CS must be 
weighed up against the risk of death 
from severe asthma.
ACUTE ASTHMA ATTACKS
Acute attacks of asthma come on sud-
denly.  They may occur in patients with 
well-controlled asthma, but usually are 
an indication of failure of the long-term 
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management plan.  The patient with 
acute asthma presents with cough 
and wheezing, shortness of breath, in-
creased work of breathing and anxiety. 
Precipitants of acute asthma episodes 
include viral upper respiratory tract 
infections (especially rhinovirus infec-
tions), allergen exposure and other 
environmental factors.  The fundamental 
problem in acute asthma is abnormal 
narrowing of the airways.  The three ma-
jor factors affecting the size of the airway 
lumen are smooth muscle constriction, 
mucosal oedema and mucus plugs.
ASSESSING THE PATIENT
The initial assessment of the patient with 
an acute asthma attack is important, as 
acute asthma may result in death.  Find-
ings suggesting a severe attack plac-
ing the patient at risk of dying include 
disturbance in level of consciousness, 
inability to speak and/or feed, severely 
diminished or absent breath sounds, 
and central cyanosis.  Other indications 
of the severity of an attack include the 
use of accessory muscles while breath-
ing.
Non-invasive objective measures, 
which aid in the assessment of the 
patient with acute asthma, include the 
peak expiratory flow rate (PEF) and 
pulse oximetry (oxygen saturation of the 
blood).
CLASSIFICATION OF THE SEVERITY 
OF THE ASTHMA ATTACK
The severity of the asthma attack guides 
the management of the patient. GINA 
identifies four groups of severity of asth-
ma attacks: mild, moderate, severe and 
imminent respiratory arrest.6 Patients at 
high risk for fatal asthma also include:
•  Previous ICU admission for asthma, 
especially if mechanical ventilation 
required
•  Current or very recent treatment with 
prednisone
•  Hospitalisation or emergency de-
partment visit for asthma in the past 
year
•  Not currently using inhaled cortico-
steroids
•  History of psychiatric disorder or 
psychosocial problems
•  Excessive use of short-acting in-
haled ß2 agonist (e.g. salbutamol)
The British Guideline7 uses a similar ap-
proach to GINA regarding the severity 
of an acute asthma attack, and here the 
two guidelines are combined in the fol-
lowing classification:
Life threatening asthma
This type of asthma attack must be 
recognised and treated immediately. 
Characteristics of these patients include 
one or more of the following:
• Inability to speak
• Exhaustion
• Confusion or drowsiness
• Wheezing not audible (“silent chest”)
• Marked accessory muscle use
• Slow pulse rate (bradycardia)
• Cyanosis
•  Unable to blow PEF meter or PEF < 
33% best or predicted
Severe asthma attack
This is also a serious type of attack and 
requires immediate recognition and 
treatment.  Characteristics of these 
patients include one or more of the fol-
lowing:
• Breathless at rest
•  Only able to speak single words be-
cause of shortness of breath
•  Young child too short of breath to 
feed
• Marked agitation
•  Increased respiratory rate (age-de-
pendent)
• Accessory muscle use
• Loud wheezing
•  Tachycardia > 120/min (> 130/min 
for children)
• PEF 33 - 50% of best or predicted
Moderate asthma attack
Characteristics of these patients include 
one or more of the following:
• Increasing symptoms
•  Able to speak phrases but still short 
of breath
•  Increased respiratory rate (age-de-
pendent)
• Some accessory muscle use
• Clearly audible wheezing
• PEF 50 - 70% of best or predicted
• No features of severe asthma
Mild asthma attack
Characteristics of these patients include 
one or more of the following:
• Able to speak in sentences
•  Moderate wheezing or wheezing 
only on expiration
•  Pulse rate < 100/min (< 120/min for 
children)
• PEF > 70% of best or predicted
WHEN SHOULD PATIENTS WITH 
ACUTE ASTHMA BE REFERRED?
Any patient with features of severe or 
life-threatening asthma should be re-
ferred to hospital. Patients with features 
of a life threatening or near fatal attack 
should be admitted, as well as patients 
with severe asthma that persists after 
initial treatment.
THERAPY OF ACUTE ASTHMA
The standard treatment of acute asthma 
attacks consists of repeated doses of 
rapidly acting inhaled bronchodilators, 
systemic corticosteroids, and oxygen.6
STANDARD MANAGEMENT OF 
ACUTE ASTHMA
Oxygen – the first step
Patients with life-threatening asthma, 
severe asthma or with oxygen satura-
tions less than 92% should receive high 
concentrations of inspired oxygen (usu-
ally 40 - 60%) via a high flow face mask.7 
Unlike patients with chronic obstructive 
pulmonary disease there is very little 
danger in precipitating hypercapnoea 
(high CO2 levels). Oxygen driven nebu-
lisers are the preferred method of bron-
chodilator delivery in hospitals, but in 
situations where these are unavailable, 
it should not prevent nebulised therapy 
from being given if indicated.
Beta-2 agonist bronchodilators – the 
second step
Inhaled ß2 agonists form the mainstay 
of the therapy of acute asthma. They 
stimulate ß2 receptors on airway smooth 
muscle, resulting in smooth muscle 
relaxation. The most commonly used 
agents in South Africa are salbutamol 
and fenoterol. They may be delivered 
by nebulisation or pressurised metered 
dose inhaler (pMDI) with a spacer (4 
- 6 puffs, each inhaled separately).7, 8, 9 
If using a nebuliser, the mask must fit 
closely. A pMDI plus spacer is the op-
timal drug delivery device for the treat-
ment of mild to moderate acute asthma.
Repeated doses of ß2 agonists 
should be administered at 15 - 30 min-
ute intervals.
Steroid therapy – the next step
Corticosteroids (CS) constitute first-line 
treatment for acute asthma, as the un-
derlying cause of asthma is inflamma-
tion. They have been shown to decrease 
mortality, relapses, hospital admission 
and bronchodilator use. The earlier 
they are administered in the acute at-
tack, the better the outcome. Steroid 
tablets or liquid are as effective as 
injected steroids, provided the patient 
is able to swallow and is not vomiting.7, 
10 The usual dose of oral prednisone or 
prednisolone is 2 mg/kg/day or 40 - 50 
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mg daily in adults. Intravenous steroids 
include hydrocortisone, methylpred-
nisolone and dexamethasone. Steroids 
should be given for at least five days or 
until the patient has recovered from the 
acute attack. It is unnecessary to taper 
the steroid dose.
Ipratropium bromide
Anticholinergics such as ipratropium 
bromide (IB) cause bronchodilatation. 
The combination of nebulised IB with a 
nebulised ß2 agonist has been shown to 
result in greater bronchodilatation than 
a ß2 agonist alone.
11 The most severely 
affected patients benefit the most, and 
IB should be considered in combination 
with inhaled ß2 agonists in the more se-
vere forms of asthma, especially early in 
the acute attack, or if there is an incom-
plete response to inhaled ß2 agonists on 
their own.
OTHER ISSUES IN THE MANAGE-
MENT OF ACUTE ASTHMA
The above constitutes standard therapy 
for acute asthma in adults and children, 
and the majority of patients will respond. 
The following therapies may be consid-
ered in the management of acute severe 
asthma not responding to the standard 
treatment.
Magnesium sulphate
A single dose of IV magnesium sulphate 
has been shown to be safe and effec-
tive in those patients with acute severe 
asthma who have had a poor response 
to initial therapy.  The response to mag-
nesium appears to be best in patients 
who present with very severe illness.12 
The dose is 25 - 50 mg/kg/dose (maxi-
mum 2 g) by slow IV infusion.
Intravenous salbutamol
The use of IV salbutamol (15 mcg/kg as 
a once-off dose) in the early manage-
ment of acute severe asthma in children 
presenting to the emergency depart-
ment (ED) has been shown to reduce 
the duration of the exacerbation and 
hasten the discharge from hospital of 
the children.13 In the intensive care unit 
IV salbutamol by continuous infusion is 
effective and probably safer than ami-
nophylline.
Intravenous aminophylline
Theophylline and its water-soluble salt 
aminophylline are methylxanthine de-
rivatives that have largely fallen out of 
favour due to their narrow therapeutic 
index and potentially severe side-ef-
fects (cardiac arrhythmias, convul-
sions). Aminophylline is not indicated 
in patients with mild to moderate acute 
asthma, but it may be used in cases of 
near fatal or life threatening asthma in 
the intensive care unit.
Adrenaline
Adrenaline 0.01 ml/kg of a 1:1000 solu-
tion administered subcutaneously may 
be used in patients who are moribund 
on presentation to the ED, or where in-
haled therapy is not available.
Inhaled steroids (ICS)
The usual role of inhaled steroids is in 
the maintenance therapy of chronic 
asthma.  ICS may improve airflow in 
acute asthma, with a more rapid onset 
than systemic steroids if administered 
in very high doses.  The biggest dis-
advantage is the cost of the ICS com-
pared to prednisone.  Maintenance 
doses of ICS should be continued or 
started as soon as possible to form the 
basis of the chronic asthma manage-
ment plan.
Antibiotics
These are not routinely indicated in 
acute asthma, which is usually precipi-
tated by viral infections.
Intravenous fl uids
Patients with prolonged severe asthma 
may become dehydrated as a result of 
poor intake or vomiting.  It is, however, 
inadvisable to overhydrate patients with 
acute asthma, and the recommended 
IV fluid volume in children should not 
exceed 50 ml/kg/24 hours.
HOSPITAL DISCHARGE AND FOL-
LOW UP7
It is difficult to define when patients 
can safely be discharged after being 
admitted with acute asthma.  They 
should certainly be on treatment that 
they could manage at home, and be 
receiving minimal inhaled ß2 agonists. 
They should receive asthma education 
with the emphasis placed on treatment 
and inhaler technique. They should 
be discharged on appropriate mainte-
nance therapy, with an action plan to 
manage exacerbations. They should 
have a follow up appointment with their 
primary care provider within a week of 
discharge.  
See CPD Questionnaire, page 41
 P  This article has been peer reviewed
REFERENCES
1.  Levin M. Asthma prevalence in Cape Town: 
urban-rural gradients, class, culture and lan-
guage. S A Respir J 2006;12(1):14-18.
2.  Moore WC, Peters S. Severe asthma: An 
overview. J Allergy Clin Immunol 2006;117:
487-94.
3.  Wenzel S, Szefler SJ. Managing severe asth-
ma. J Allergy Clin Immunol 2006;117:508-11.
4.  Motala C, Kling S, Gie RP et al. Guideline for 
the Management of Chronic Asthma in Chil-
dren – 2000 Update.  S Afr Med J 2000; 90(5):
524-539.
5.  Lalloo UG, Bateman ED, Feldman C et al. 
Guideline for the Management of Chronic 
Asthma in Adults – 2000 Update.  S Afr Med J 
2000; 90(5):540-52.
6.  Global Initiative for Asthma. Global Strat-
egy for Asthma Management and Prevention 
2006. www.ginasthma.org. Accessed 16 No-
vember 2006.
7.  British Thoracic Society and Scottish Intercol-
legiate Guidelines Network. British Guideline 
on the Management of Asthma Updated 
November 2005. www.brit-thoracic.org.uk/
Guidelines. Accessed 28 November 2006.
8.  Zar HJ, Brown G, Donson H et al. Home-
made spacers for bronchodilator therapy in 
children with acute asthma: A randomised 
trial. Lancet 1999; 354:979-982.
9.  Leversha AM, Campanella SG, Aickin RP, et 
al. Costs and effectiveness of spacer versus 
nebulizer in young children with moderate 
and severe acute asthma. J Pediatr 2000; 
136:497-502.
10.  Becker JM, Arora A, Scarfone RJ, et al. Oral 
versus intravenous corticosteroids in children 
hospitalised with asthma. J Allergy Clin Immu-
nol 1999; 103:586-590.
11.  Plotnick LH, Ducharme FM. Combined 
inhaled anticholinergic agents and inhaled 
beta-2 agonists for initial treatment of acute 
asthma in children (Cochrane Review). In The 
Cochrane Library Issue 3 2001.
12.  Ciarallo L, Sauer AH, Shannon MW. Intra-
venous magnesium therapy for moderate 
to severe pediatric asthma: results of a ran-
domised, placebo-controlled trial. J Pediatr 
1996; 129:809-814.
13.  Browne GJ, Penna AS, Phung X, Soo M. 
Randomised trial of intravenous salbutamol in 
early management of acute severe asthma in 
children. Lancet 1997; 349:301-305.
